Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:FBIO NASDAQ:SABS NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.40-0.4%$2.51$0.96▼$3.87$219.06M2.48759,718 shs350,700 shsFBIOFortress Biotech$2.77+0.4%$2.50$1.70▼$4.53$91.68M1.22465,429 shs284,942 shsSABSSAB Biotherapeutics$3.33-1.5%$3.70$1.60▼$6.60$258.45M0.54385,601 shs355,795 shsVSTMVerastem$4.10+4.1%$4.98$3.55▼$11.24$346.22M0.272.23 million shs1.60 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+2.55%-13.93%-5.12%+49.69%+2.12%FBIOFortress Biotech-0.36%-0.36%+22.12%-10.97%+31.43%SABSSAB Biotherapeutics+2.11%-2.59%-6.63%-18.55%+79.79%VSTMVerastem+4.79%+2.07%-14.90%-29.64%-34.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.40-0.4%$2.51$0.96▼$3.87$219.06M2.48759,718 shs350,700 shsFBIOFortress Biotech$2.77+0.4%$2.50$1.70▼$4.53$91.68M1.22465,429 shs284,942 shsSABSSAB Biotherapeutics$3.33-1.5%$3.70$1.60▼$6.60$258.45M0.54385,601 shs355,795 shsVSTMVerastem$4.10+4.1%$4.98$3.55▼$11.24$346.22M0.272.23 million shs1.60 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+2.55%-13.93%-5.12%+49.69%+2.12%FBIOFortress Biotech-0.36%-0.36%+22.12%-10.97%+31.43%SABSSAB Biotherapeutics+2.11%-2.59%-6.63%-18.55%+79.79%VSTMVerastem+4.79%+2.07%-14.90%-29.64%-34.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.00Hold$5.00108.33% UpsideFBIOFortress Biotech 2.25Hold$17.00513.72% UpsideSABSSAB Biotherapeutics 2.80Moderate Buy$11.00230.33% UpsideVSTMVerastem 2.91Moderate Buy$15.60280.49% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, VSTM, SABS, and CDXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026VSTMVerastem Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026SABSSAB Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/18/2026FBIOFortress Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026VSTMVerastem MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $14.005/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.005/8/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$70.39M3.10N/AN/A$0.56 per share4.29FBIOFortress Biotech$63.26M1.45N/AN/A$2.00 per share1.39SABSSAB Biotherapeutics$1.32M192.89$0.34 per share9.89$3.18 per share1.05VSTMVerastem$30.91M11.66N/AN/A$0.74 per share5.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)FBIOFortress Biotech$6.82M$3.170.871.83N/A193.12%109.66%45.56%8/13/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)VSTMVerastem-$209.47M-$2.70N/AN/AN/A-391.17%-486.40%-91.56%8/6/2026 (Estimated)Latest FBIO, VSTM, SABS, and CDXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.945.365.23FBIOFortress Biotech0.182.862.77SABSSAB Biotherapeutics0.0111.4511.45VSTMVerastem0.893.043.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%FBIOFortress Biotech96.51%SABSSAB Biotherapeutics7.82%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipCDXSCodexis3.50%FBIOFortress Biotech28.50%SABSSAB Biotherapeutics25.06%VSTMVerastem1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.90 million87.72 millionOptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableSABSSAB Biotherapeutics14076.46 million57.30 millionNot OptionableVSTMVerastem5087.87 million86.17 millionOptionableFBIO, VSTM, SABS, and CDXS HeadlinesRecent News About These CompaniesVSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next KeytrudaJune 5, 2026 | finance.yahoo.comVerastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerJune 3, 2026 | businesswire.comVerastem Oncology to Present at Jefferies Healthcare ConferenceMay 27, 2026 | businesswire.comVerastem Oncology Appoints Michael P. Bailey to its Board of DirectorsMay 26, 2026 | pharmiweb.comPVerastem Shareholders Back Board, Executive Pay and PlansMay 26, 2026 | tipranks.comVerastem IncMay 23, 2026 | money.usnews.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comVerastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 18, 2026 | zacks.comVerastem (VSTM) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comVerastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesMay 8, 2026 | finance.yahoo.comOn World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian CancerMay 8, 2026 | businesswire.comVerastem, Inc. (VSTM) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVerastem (VSTM) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVerastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerApril 30, 2026 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy†from AnalystsApril 24, 2026 | defenseworld.netDVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comBuy Rating on Verastem: Favorable Risk‑Reward for VS‑7375 Driven by Superior Early Efficacy vs. Zoldonrasib and Improving Safety OutlookApril 21, 2026 | tipranks.comVectoring In On VerastemApril 20, 2026 | seekingalpha.comVerastem Inc.April 16, 2026 | barrons.comReaffirming Buy on Durable AVMAPKI FAKZYNJA Benefit in Recurrent LGSOC, Supported by Robust 2-Year RAMP 201 DataApril 10, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, VSTM, SABS, and CDXS Company DescriptionsCodexis NASDAQ:CDXS$2.40 -0.01 (-0.41%) As of 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$2.77 +0.01 (+0.36%) Closing price 04:00 PM EasternExtended Trading$2.74 -0.03 (-1.08%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.SAB Biotherapeutics NASDAQ:SABS$3.33 -0.05 (-1.48%) Closing price 04:00 PM EasternExtended Trading$3.52 +0.19 (+5.56%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Verastem NASDAQ:VSTM$4.10 +0.16 (+4.06%) Closing price 04:00 PM EasternExtended Trading$4.05 -0.05 (-1.22%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
